Carlson Capital’s Stemline Therapeutics, Inc. STML Stock Holding History

Carlson Capital’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-128,349	Closed	-$621K	–	265
2020 Q1	$621K	Sell	128,349 -133,000	-51%	-$862K	0.02%	184
2019 Q4	$2.78M	Buy	261,349 +68,349	+35%	+$679K	0.05%	191
2019 Q3	$2.01M	Sell	193,000 -205,400	-52%	-$2.69M	0.04%	200
2019 Q2	$6.1M	Sell	398,400 -52,068	-12%	-$753K	0.09%	203
2019 Q1	$5.79M	Buy	+450,468	New	+$5.09M	0.1%	196

Carlson Capital's STML Position: Q2 2020 in Review

Carlson Capital sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 128,349 shares — an estimated $621K sold.

Carlson Capital first reported a position in STML in Q1 2019 and held it in 5 quarters. The position peaked at $6.1M in Q2 2019. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.

Carlson Capital reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
Carlson Capital sold 128,349 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $621K.
Carlson Capital first reported a position in Stemline Therapeutics, Inc. in Q1 2019 and held it in 5 quarters.
Carlson Capital's Stemline Therapeutics, Inc. position peaked at $6.1M in Q2 2019.
0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.

Based on Carlson Capital's 13F filing for Q2 2020, filed 14 Aug 2020.